Τίτλος:
A viral kinetic study using pegylated interferon alfa-2b and/or
lamivudine in patients with chronic hepatitis B/HBeAg negative
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
We studied viral dynamic parameters in 44 chronic hepatitis B/hepatitis
B e antigen (HBeAg)(-) patients treated with pegylated interferon
alfa-2b (PEG-IFN) 100 or 200 mu g weekly or lamivudine 100 mg daily or
the combination of PEG-IFN 100 or 200 mu g with lamivudine. Patients
receiving PEG-IFN monotherapy exhibited viral load oscillations between
weekly injections, which were resolved by the addition of lamivudine.
The median pharmacological delay was estimated at 4.1, 5.8, and 1.8
hours in PEG-IFN monotherapy, PEG-IFN 100/200 mu g + lamivudine, and
lamivudine monotherapy, respectively (P =.44). The median half-life of
free virus was 12.7 hours (range, 2.4-69.2 hours). The mean antiviral
effectiveness of PEG-IFN 100/200 mu g monotherapy was lower than that of
lamivudine (82.6% vs. 96.4%; P =.005). The mean effectiveness of
PEG-IFN 100 mu g + lamivudine and PEG- IFN 200 mu g + lamivudine was
92.8% and 94.4%, respectively. The half-life of infected cells ranged
from 2.7 to 75 days. The median half-life of infected cells in patients
receiving the combination regimens of PEG-IFN and lamivudine was similar
to that of lamivudine patients (5-0 days vs. 6.0 days, P =.77). In
conclusion, the addition of pegylated interferon alfa-2b in lamivudine
treatment was found to neither enhance the potency of blocking HBV
production nor the decay rates of infected cells.
Συγγραφείς:
Sypsa, VA
Mimidis, K
Tassopoulos, NC
Chrysagis, D and
Vassiliadis, T
Moulakakis, A
Raptopoulou, M
Haida, C and
Hatzakis, A
Περιοδικό:
WORLD JOURNAL OF HEPATOLOGY
